Unresectable Hepatocellular Carcinoma Market Report 2025

The unresectable hepatocellular carcinoma market size has grown marginally in recent years. It will grow from $1.98 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to chemotherapy advances, clinical trial outcomes, liver transplantation limitations, increased cancer cases, expanded access to therapies.

The unresectable hepatocellular carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.95 billion in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to healthcare policy changes, patient stratification strategies, real-world evidence utilization, patient advocacy and awareness, economic and dynamics. Major trends in the forecast period include precision medicine and biomarkers, real-world evidence and data integration, multidisciplinary approaches, global clinical trials and collaborations, and patient-centric care.

The rising prevalence of liver cancer is propelling the growth of the unresectable hepatocellular carcinoma market moving forward. Liver cancer occurs when healthy liver cells are overtaken by tumor cells that begin to grow uncontrollably. Unresectable hepatocellular carcinoma is a form of cancer that is treated through liver transplantation and radiofrequency ablation. For example, in October 2022, the Journal of Hepatology, a peer-reviewed scientific journal based in Switzerland, reported that globally, 830,200 individuals died from liver cancer in 2020, with an anticipated 1.4 million new liver cancer cases expected between 2020 and 2040, reflecting a 55% increase in new cases annually. Additionally, in January 2024, the American Cancer Society, a US-based non-profit organization, projected that around 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. in 2024 (28,000 in men and 13,630 in women), with approximately 29,840 deaths expected (19,120 men and 10,720 women). Therefore, the increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market.

The growth in healthcare expenditure is anticipated to drive the unresectable hepatocellular carcinoma market forward. Healthcare expenditure encompasses the total financial resources allocated to activities aimed at promoting, restoring, and maintaining health. As unresectable hepatocellular carcinoma progresses and becomes more complex, treatment options tend to become costlier. For example, in 2021, health spending experienced an average increase of approximately 6%, while a report by JPMorgan Chase & Co. in May 2022 revealed an overall 23% surge in healthcare spending in the same year. The growing healthcare expenditure is expected to be a significant driver in the expansion of the unresectable hepatocellular carcinoma market.

The increasing consumption of beer is anticipated to drive the growth of the unresectable hepatocellular carcinoma market moving forward. Beer consumption refers to the act of drinking beverages that contain ethyl alcohol, specifically beer. Excessive alcohol intake, including beer, is a well-recognized risk factor for developing hepatocellular carcinoma (HCC). Chronic alcohol use can harm liver cells, resulting in inflammation, fibrosis, and eventually cirrhosis, creating a conducive environment for HCC development. For instance, in December 2023, data published by Kirin Holdings Co. Ltd., a Japan-based company specializing in alcoholic and non-alcoholic beverages and pharmaceuticals, revealed that global beer consumption increased by approximately 5.4 million kiloliters in 2022, equivalent to about 8.5 billion bottles (633 ml each) compared to the previous year. Therefore, the rising beer consumption is contributing to the growth of the unresectable hepatocellular carcinoma market.

Innovations in products emerge as a notable trend gaining traction in the unresectable hepatocellular carcinoma market. Major companies operating in this market are actively pursuing the development of innovative products to maintain their market positions. For instance, AstraZeneca, a pharmaceutical and biotechnology company based in the UK, introduced Imjudo (tremelimumab) in combination with Imfinzi for unresectable liver cancer. This treatment, known as the STRIDE regimen, involves a single dose of anti-CTLA-4 antibody Imjudo 300mg combined with anti-PD-L1 antibody Imfinzi 1500 mg every four weeks. Patients receiving this combination showed a 22% lower chance of mortality compared to those receiving sorafenib.

Major players in the unresectable hepatocellular carcinoma market are focusing on the development of combination therapies to address the complexities of this condition. For example, Ono Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched Opdivo (nivolumab) Intravenous Infusion in combination with Yervoy in March 2023. Opdivo, a human anti-human PD-1 monoclonal antibody, works by blocking the interaction between PD-1 on T cells and its ligands on cancer cells, thereby enhancing T cells' ability to recognize and eliminate cancer cells more effectively. This development reflects the commitment of major companies to provide effective therapeutic options for unresectable hepatocellular carcinoma conditions.

Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.

North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the unresectable hepatocellular carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Unresectable hepatocellular carcinoma refers to an aggressive tumor that commonly develops in conjunction with cirrhosis and chronic liver disease. Treatment options for unresectable hepatocellular carcinoma include surgical resection, liver transplant, ablation, and embolization.

The main types of unresectable hepatocellular carcinoma are primary, secondary, and benign liver growth. In this context, 'primary' signifies a greater significance, and as the most prevalent form of primary liver cancer, hepatocellular carcinoma is particularly noteworthy. Various treatment approaches, such as chemotherapy, molecularly targeted therapy, immunotherapy, and others, are employed in hospitals, specialty clinics, and cancer centers.

The unresectable hepatocellular carcinoma market research report is one of a series of new reports that provides unresectable hepatocellular carcinoma market statistics, including unresectable hepatocellular carcinoma industry global market size, regional shares, competitors with a unresectable hepatocellular carcinoma market share, detailed unresectable hepatocellular carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the unresectable hepatocellular carcinoma industry. This unresectable hepatocellular carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The unresectable hepatocellular carcinoma market includes revenues earned by entities by providing first-line agents, surgical resection, and liver transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.